This First-in-Human (FIH) Phase 1/2 study will evaluate mRNA-3704 in patients with methylmalonic acidemia/aciduria (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency between 1 to 18 years of age with elevated plasma methylmalonic acid. The study is designed to characterize baseline biomarker levels followed by assessment of safety, pharmacokinetics, and pharmacodynamics of different doses of mRNA-3704 in patients affected by MMA as part of the Dose Escalation phase. During the Dose Escalation phase, three dose levels of mRNA-3704 are planned to be investigated in this study among patients with MMA due to MUT deficiency: low dose, mid dose, and high dose. An additional cohort to evaluate a fourth dose level may be considered jointly by the independent SMC and the Sponsor. Upon establishment of a dose with acceptable safety and pharmacodynamic activity, additional patients will be enrolled in a Dose Expansion phase to allow for further characterization of the safety and pharmacodynamics of mRNA-3704. Patients in both phases of study will participate in a pre-dosing observational period, followed by a treatment period, and then a follow-up period after withdrawal of treatment.
Methylmalonic Acidemia (MMA), Metabolism, Inborn Errors
Patients are eligible to be included in the study only if all of the following criteria apply:
Confirmed diagnosis of isolated MMA due to MUT deficiency based on the following criteria:
Elevated plasma methylmalonic acid concentrations (≥ 100 µmol/L)
Presence of normal serum/plasma Vitamin B12 and plasma homocysteine levels
Confirmed diagnosis by molecular genetic testing
Patient must be ≥ 1 year of age at the time of consent/assent (Inclusion of the first three patients will be restricted to individuals age ≥ 8 years)
Patients are excluded from the study if any of the following criteria apply:
Diagnosis of isolated MMA cblA, cblB, or cblD enzymatic subtypes or methylmalonyl-CoA epimerase deficiency or combined MMA with homocystinuria
History of organ transplantation
Previously received gene therapy for the treatment of MMA.
Estimated glomerular filtration rate (GFR) < 30 mL/min/1.73 m2; or patients who receive chronic dialysis
Phase 1, Phase 2
November 13, 2020
Primary Contact Information
For more information on this trial, visit clinicaltrials.gov.
For more information and to contact the study team: